Every 10-Q that Mangoceuticals, Inc. (MGRX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow MGRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MGRX filings page.
Mangoceuticals, Inc., a men’s wellness telemedicine company, reported Q2 2026 revenue of $68,757, down from $168,109 in Q2 2025, with six‑month 2026 revenue of $136,621 versus $277,415 a year earlier. Despite lower sales, the Q2 2026 net loss attributable to the company narrowed to $1,312,653 from $5,415,818, helped by sharply reduced operating expenses, including lower stock‑based compensation.
Cash and cash equivalents declined to $228,688 at June 30, 2026 from $1,486,338 at December 31, 2025, while net cash used in operating activities was $1,571,849 for the first half of 2026. Stockholders’ equity fell to $12,523,826 from $15,199,005, with an accumulated deficit of $45,363,283. Shares outstanding increased to 18,017,421 common shares from 15,888,795, reflecting equity raises and preferred stock conversions.
Non‑current assets are dominated by acquired patents and licenses with a net carrying amount of $13,553,272, supported by ongoing Phase II clinical work on respiratory illness prevention technology and the Dermytol® skin‑care distribution rights. The company continues to rely on related‑party structures, including Mango & Peaches and a related‑party compounding pharmacy, and notes material prior‑year impairment of its Dermytol® master distribution agreement.
Mangoceuticals, Inc. reported first-quarter 2026 results showing modest revenue and continued investment-driven losses. Revenue was $67,864 for the three months ended March 31, 2026, down from $109,306 a year earlier, producing gross profit of $29,001.
The company recorded a net loss of $3,403,141, compared with a $4,839,489 loss in the prior-year quarter, and a basic and diluted loss per share of $0.22. Operating expenses totaled $3,155,327, including $1,647,821 of stock-based compensation, reflecting heavy spending on growth and compensation.
Cash and cash equivalents fell to $174,562 from $1,486,338 at year-end 2025, driven by $1,311,343 of net cash used in operating activities. Total assets were $14,449,223, largely consisting of $13.8 million in acquired patents and licenses, which the company views as key to future men’s health and dermatology product opportunities.
Mangoceuticals, Inc. (MGRX) filed Amendment No. 1 to its Q2 2025 Form 10‑Q to correct the Exhibit 32.1 hyperlink, add Item 408(a) disclosures, and include related XBRL tagging. The amendment is presented as of the original filing date and does not otherwise update prior disclosures.
For the quarter ended June 30, 2025, revenue was $168,109 with a net loss of $5,415,820. For the first half of 2025, revenue totaled $277,415, gross profit $152,012, and net loss $10,255,309. Operating expenses for the first half were $10,273,696, including $4,165,924 of stock‑based compensation. Cash and cash equivalents were $101,019 at June 30, 2025. Shares outstanding were 10,535,791 as of August 14, 2025.
The balance sheet reflects $20,694,893 of net intangible assets (acquired patents and license) and total stockholders’ equity of $19,243,064 at June 30, 2025. The previously disclosed 1‑for‑15 reverse stock split effective October 16, 2024 has been retroactively reflected throughout.